Similar articles

• High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench.

  Levy Y. Levy Y. Cardiovasc Res. 2008 Mar 1;77(4):614-5. doi: 10.1093/cvr/cvn003. Epub 2008 Jan 10. Cardiovasc Res. 2008. PMID: 18187459 No abstract available.
• Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?

  Page MM, Hooper AJ, Burnett JR. Page MM, et al. Expert Opin Pharmacother. 2016;17(2):275-81. doi: 10.1517/14656566.2016.1129402. Epub 2015 Dec 28. Expert Opin Pharmacother. 2016. PMID: 26642232 Review.
• [Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].

  Einecke D. Einecke D. MMW Fortschr Med. 2011 Dec 8;153(49-50):17-8. doi: 10.1007/BF03369190. MMW Fortschr Med. 2011. PMID: 22308584 German. No abstract available.
• Dissociating HDL cholesterol from cardiovascular risk.

  Hausenloy DJ, Opie L, Yellon DM. Hausenloy DJ, et al. Lancet. 2010 Jul 31;376(9738):305-6. doi: 10.1016/S0140-6736(10)61021-5. Epub 2010 Jul 23. Lancet. 2010. PMID: 20655104 No abstract available.
• [HDL and CETP in atherogenesis].

  Pöss J, Böhm M, Laufs U. Pöss J, et al. Dtsch Med Wochenschr. 2010 Feb;135(5):188-92. doi: 10.1055/s-0030-1247862. Epub 2010 Jan 15. Dtsch Med Wochenschr. 2010. PMID: 20082258 Review. German.